Browse NALCN

Summary
SymbolNALCN
Namesodium leak channel, non selective
Aliases bA430M15.1; CanIon; VGCNL1; voltage gated channel like 1; sodium leak channel, non-selective; CLIFAHDD; IHPR ......
Chromosomal Location13q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Multi-pass membrane protein
Domain PF00520 Ion transport protein
Function

Voltage-independent, cation-nonselective channel which is permeable to sodium, potassium and calcium ions. Regulates the resting membrane potential and controls neuronal excitability (PubMed:17448995). Neuropeptides such as neurotensin and substance P (SP) stimulate the firing of action potentials by activating NALCN through a SRC family kinases-dependent pathway. In addition to its baseline activity, NALCN activity is enhanced/modulated by several GPCRs. Required for normal respiratory rhythm and neonatal survival. Involved in systemic osmoregulation by controlling the serum sodium concentration. NALCN is partly responsible for the substance P-induced depolarization and regulation of the intestinal pace-making activity in the interstitial cells of Cajal. Plays a critical role in both maintenance of spontaneous firing of substantia nigra pars reticulata (SNr) neurons and physiological modulation of SNr neuron excitability (By similarity).

> Gene Ontology
 
Biological Process GO:0001508 action potential
GO:0006813 potassium ion transport
GO:0006814 sodium ion transport
GO:0006816 calcium ion transport
GO:0015672 monovalent inorganic cation transport
GO:0034762 regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0035725 sodium ion transmembrane transport
GO:0042391 regulation of membrane potential
GO:0051899 membrane depolarization
GO:0060075 regulation of resting membrane potential
GO:0070588 calcium ion transmembrane transport
GO:0070838 divalent metal ion transport
GO:0071804 cellular potassium ion transport
GO:0071805 potassium ion transmembrane transport
GO:0072511 divalent inorganic cation transport
GO:0086010 membrane depolarization during action potential
Molecular Function GO:0005216 ion channel activity
GO:0005244 voltage-gated ion channel activity
GO:0005261 cation channel activity
GO:0005272 sodium channel activity
GO:0015077 monovalent inorganic cation transmembrane transporter activity
GO:0015081 sodium ion transmembrane transporter activity
GO:0015267 channel activity
GO:0022803 passive transmembrane transporter activity
GO:0022832 voltage-gated channel activity
GO:0022836 gated channel activity
GO:0022838 substrate-specific channel activity
GO:0022840 leak channel activity
GO:0022842 narrow pore channel activity
GO:0046873 metal ion transmembrane transporter activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-983712: Ion channel transport
R-HSA-2672351: Stimuli-sensing channels
R-HSA-382551: Transmembrane transport of small molecules
Summary
SymbolNALCN
Namesodium leak channel, non selective
Aliases bA430M15.1; CanIon; VGCNL1; voltage gated channel like 1; sodium leak channel, non-selective; CLIFAHDD; IHPR ......
Chromosomal Location13q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NALCN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolNALCN
Namesodium leak channel, non selective
Aliases bA430M15.1; CanIon; VGCNL1; voltage gated channel like 1; sodium leak channel, non-selective; CLIFAHDD; IHPR ......
Chromosomal Location13q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NALCN in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNALCN
Namesodium leak channel, non selective
Aliases bA430M15.1; CanIon; VGCNL1; voltage gated channel like 1; sodium leak channel, non-selective; CLIFAHDD; IHPR ......
Chromosomal Location13q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NALCN in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1630.489
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1280.797
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3770.34
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1470.794
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.8210.629
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.7060.734
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.8230.357
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.5280.22
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3430.798
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0240.975
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.830.406
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3520.164
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NALCN in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141728.6028.60.0318
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103400400.497
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.88.26.60.452
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.810.24.60.718
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.26.2160.53
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.5010.50.135
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.6013.60.279
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNALCN
Namesodium leak channel, non selective
Aliases bA430M15.1; CanIon; VGCNL1; voltage gated channel like 1; sodium leak channel, non-selective; CLIFAHDD; IHPR ......
Chromosomal Location13q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NALCN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNALCN
Namesodium leak channel, non selective
Aliases bA430M15.1; CanIon; VGCNL1; voltage gated channel like 1; sodium leak channel, non-selective; CLIFAHDD; IHPR ......
Chromosomal Location13q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NALCN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NALCN.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNALCN
Namesodium leak channel, non selective
Aliases bA430M15.1; CanIon; VGCNL1; voltage gated channel like 1; sodium leak channel, non-selective; CLIFAHDD; IHPR ......
Chromosomal Location13q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NALCN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNALCN
Namesodium leak channel, non selective
Aliases bA430M15.1; CanIon; VGCNL1; voltage gated channel like 1; sodium leak channel, non-selective; CLIFAHDD; IHPR ......
Chromosomal Location13q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NALCN expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNALCN
Namesodium leak channel, non selective
Aliases bA430M15.1; CanIon; VGCNL1; voltage gated channel like 1; sodium leak channel, non-selective; CLIFAHDD; IHPR ......
Chromosomal Location13q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NALCN and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNALCN
Namesodium leak channel, non selective
Aliases bA430M15.1; CanIon; VGCNL1; voltage gated channel like 1; sodium leak channel, non-selective; CLIFAHDD; IHPR ......
Chromosomal Location13q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NALCN collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.